In the framework of the legal proceeding, which ended two years ago, Proneuron contended that Teva had done everything in its power to prevent the market from raising the possibility of administering Copaxone less frequently. For example, Proneuron presented in court a Teva work plan stating, "Because Copaxone is being marketed for multiple sclerosis as a daily injection, it is clear that the same product cannot be used for glaucoma less frequently without creating commercial problems." At a meeting at Teva to discuss a trial for treatment of glaucoma, according to the documents submitted by Proneuron, it was stated that "Presenting two different treatment regimes for multiple sclerosis and nerve degeneration diseases is liable to affect Copaxone's market share, because neurologists are liable to also consider a less frequent regime for multiple sclerosis."